GAO: FDA does poor job of post-approval drug safety monitoring

04/23/2006 | Washington Post (tiered subscription model), The

A report by the Government Accountability Office says the FDA is too slow in picking up and responding to safety issues of drugs already on the market. The FDA also lacks clear policies for dealing with drug safety issues and often fails to include its best safety experts in important meetings, the report found. The GAO suggested Congress widen FDA's authority to require drug companies to conduct studies of drugs on the market.

View Full Article in:

Washington Post (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ